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Abstract Medication-overuse headache (MOH) is a
chronic disorder associated with overuse of analgesic
drugs, triptans, non-steroidal anti-inﬂammatory drugs
(NSAIDs) or other acute headache compounds. Various
epidemiologic investigations proved that different drug
types could cause nephrotoxicity, particularly in chronic
patients. The aim of the present work was to analyze, by a
proteomic approach, the urinary protein proﬁles of MOH
patients focusing on daily use of NSAIDs, mixtures and
triptans that could reasonably be related to potential renal
damage. We selected 43 MOH patients overusing triptans
(n = 18), NSAIDs (n = 11), and mixtures (n = 14), for
2–30 years with a mean daily analgesic intake of 1.5 ± 0.9
doses, and a control group composed of 16 healthy
volunteers. Urine proteins were analyzed by mono-
dimensional gel electrophoresis and identiﬁed by mass
spectrometry analysis. Comparing the proteomic proﬁles of
patients and controls, we found a signiﬁcantly different
protein expression, especially in the NSAIDs group, in
which seven proteins resulted over-secreted from kidney
(OR = 49, 95% CI 2.53–948.67 vs. controls; OR = 11.6,
95% CI 0.92–147.57 vs. triptans and mixtures groups). Six
of these proteins (uromodulin, a-1-microglobulin, zinc-a-2-
glycoprotein, cystatin C, Ig-kappa-chain, and inter-a-tryp-
sin heavy chain H4) were strongly correlated with various
forms of kidney disorders. Otherwise, in mixtures and in
triptans abusers, only three proteins were potentially
associated to pathological conditions (OR = 4.2, 95% CI
0.33–53.12, vs. controls). In conclusion, this preliminary
proteomic study allowed us to deﬁne the urinary protein
pattern of MOH patients that is related to the abused drug.
According with the obtained results, we believe that the
risk of nephrotoxicity should be considered particularly in
MOH patients who abuse of NSAIDs.
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Introduction
The term medication-overuse headache (MOH) was
recently introduced by the International Headache Society
to describe daily or nearly daily (chronic) headache that
occurs after the regular intake (overuse) of analgesic drugs,
triptans, or other anti-headache or anti-migraine drugs [1,
2]; their excessive use for the treatment of pain conditions
led to the development of MOH in about 1.7% of the
people in Europe, Asia, and North America [3].
The molecular basis and the pathophysiology of MOH
are still largely unknown, although it has been hypothe-
sized that this condition could be mediated by cognitive
impulsivity, and shares some dysfunction mechanisms with
drug addiction [4], probably involving factors beyond
the pain alone, such as certain behaviors and psychologic
states [5]. Moreover, a combination of environmental and
genetic factors may contribute to a patient’s vulnerability
to intoxication, substance overuse, dependence and with-
drawal in MOH [6, 7]. Recently, a role of dopamine-related
genes in the genetic liability to chronic headache with drug
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tibility to medication overuse [8, 9]. Therefore, an
involvement of the serotonin transporter gene in the
development of analgesics overuse in chronic tension-type
headache patients has been postulated [10]. Hence, MOH
has been investigated in both clinical and experimental
studies, in the attempt to deﬁne its clinical picture, features
and biologic basis. To date, however, no studies have been
carried out to evaluate the possible relationship between
MOH and potential renal injury, although drug-associated
nephrotoxicity accounts for 18–27% of all acute kidney
injury cases in the USA [11]. Currently, the most pertinent
applications in nephrotoxicology can be found in the
proteomic analysis of renal drug effects [12] and in the
study of the consequences on the kidney induced by
environmental toxins, drugs and other bioactive agents,
analyzing urine [13]. Human urine is a useful biologic ﬂuid
for clinical proteomics study, as it can be collected easily
and non-invasively in large quantities, and because it is a
stable sample compared with other bioﬂuids. It has been
deﬁned as a ﬂuid biopsy of the kidney and urogenital tract,
so many changes in these organs may be detected in urine
[14, 15]. Urinary proteomics has thus become one of the
most attractive subdisciplines in clinical proteomics, par-
ticularly for biomarker discovery [16] and clinical diag-
nostics [17].
The aim of this project was to analyze the urinary pro-
teome of patients with MOH, in comparison with healthy
subjects, with the purpose to identify possible differences
in excreted proteins induced by excessive consumption of
NSAIDs, mixtures and triptans that could be related to
nephrotoxicity. We adopted a proteomic approach that is
one-dimensional sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (1D-SDS-PAGE) in conjunction with
mass spectrometry (MS) analysis, to discover and identify
potential early urinary biomarkers able to predict probable
kidney damages in MOH patients.
Materials and methods
Patients selection
Forty-three MOH patients were recruited by the ‘‘Headache
and Drug Abuse Center’’ and the ‘‘Unit of Toxicology and
Clinical Pharmacology’’ of the University Hospital of
ModenaandReggioEmilia.As shown inTable 1,they were
divided into three groups according to the type of primary
abused drug: patients who consumed exclusively triptans
(16 women and 2 men), aged 32–65 years (mean 45.7 ±
10.8), exclusively NSAIDs (11 women), aged 36–62 years
(mean 49.8 ± 7.9), and patients (13 women and 1 man)
assuming mixtures, in 90% of case containing indometacin,
caffeine and perchlorperazine, aged 35–66 years (mean
56.7 ± 11.8).
Healthy volunteers (12 women and 4 men), aged
37–65 years (mean 46.2 ± 5.4), with a history of normal
renalfunctionwerealsoenrolledandusedascontrols.Forall
study participants, exclusion criteria included: (1) proved
kidney diseases and other acute or chronic medical illness,
Table 1 Descriptive demographic, headache and clinical data of control subjects and MOH patients
Control subjects
(n = 16)
Triptans group
(n = 18)
NSAIDs group
(n = 11)
Mixtures group
(n = 14)
Total patients
(n = 43)
Age (years) 46.2 ± 5.4* 45.7 ± 10.8* 49.8 ± 7.9 56.7 ± 11.8 48.4 ± 10.5
Gender (F/M) 12/4 16/2 11/0 13/1 40/3
BMI 26.0 ± 3.5 25.3 ± 4.4 23.4 ± 4.4 25.9 ± 6.4 25.1 ± 5.0
DDI NA 1.2 ± 0.4 1.9 ± 1.4 1.6 ± 0.9 1.5 ± 0.9
MOH duration (years) NA 7.5 ± 5.8 8.6 ± 7.9 9.0 ± 9.6 8.5 ± 7.6
LDQ 14.3 ± 4.2 15.7 ± 4.5 14.3 ± 6.1 17.2 ± 4.2 15.5 ± 4.8
SBP (mmHg) 116.4 ± 12.7 116.7 ± 15.2 110 ± 10.1 119.2 ± 16.3 115.7±14.1
DBP (mmHg) 70.2 ± 8.5 71.1 ± 11.7 70.0 ± 10.1 71.7 ± 11.7 71.0 ± 10.7
Serum creatinine (mg/dL) 0.6 ± 0.2 0.8 ± 0.1 0.7 ± 0.1 0.7 ± 0.2 0.7 ± 0.1
Serum uric acid (mg/dL) 4.0 ± 1.1 3.8 ± 0.9 3.6 ± 1.3 4.3 ± 1.6 3.9 ± 1.2
Urinary pH 5.3 ± 0.7 5.7 ± 0.8 5.5 ± 0.7 6.2 ± 1.1 5.7 ± 0.9
Urine speciﬁc gravity 1013 ± 5 1018 ± 6 1014 ± 6 1012 ± 5 1015 ± 6
Data are expressed as mean ± SD. Statistical signiﬁcance was evaluated using Student’s t-test (* P\0.01 vs. mixtures group. P = 0.008 after
Bonferroni correction)
Groups: triptans (exclusively one, or more types of triptans), NSAIDs (exclusively one, or more types of NSAIDs), mixtures (consumption of
drugs containing indometacin, caffeine and sedatives)
BMI body mass index, DDI daily drug intake, MOH medication-overuse headache, LDQ Leed’s drugs questionnaire, SBP systolic blood pressure,
DBP dyastolic blood pressure
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123(2) elevated serum creatinine levels, and (3) prescription
and consumption of counter medicines (other than NSAIDs
and triptans for MOH patients). In fact, none of the
patients and controls had hypertension, inﬂammatory dis-
eases, acute or chronic medical illness, heart failure, malig-
nancy, and renal dysfunctions. Routine laboratory analyses
were carried out in all the subjects, including serum creati-
nine, uric acid, urinary pH and urine speciﬁc gravity. The
studywasapprovedbytheResearchEthicsCommitteeofthe
University Hospital of Modena, and informed consent was
provided by all volunteers and patients.
Urine samples collection and preparation
Taking into account that urine samples were investigated
by proteomic methods, ﬁrst of all we followed proper and
standardized procedures for urine collection, preparation
and storage [18].
All subjects were asked to refrain from unusual physical
activity the day before urine collection, to avoid transient
increase in protein excretion. Second void morning urine
samples were collected, discarding ﬁrst jet, but not the ﬁnal
(midstream). The urine was collected into a sterile poly-
propylene container, and immediately placed on ice. To
remove cell debris and cellular contamination, urine sam-
ples were centrifuged at 8009g for 10 min at 4C, then, the
supernatant was divided into aliquots and stored at -80C.
In normal conditions, human urine has a very diluted
protein concentration (usually does not exceed 10 mg/
100 mL), with a high-salt content. For these reasons,
before proteomic analysis, 4 mL of urine were concen-
trated and desalted using 3 kDa MW-cut off ﬁlter devices
(Millipore). By this procedure urine was concentrated
about 50-fold. Total protein concentration was estimated
by the spectrophotometric Bradford’s method [19].
One-dimensional gel electrophoresis (1D-SDS-PAGE)
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) was performed according to Laemmli’s
procedure [20], under reducing conditions. Urine samples
were pooled and 10 lg of total proteins for each group
were mixed with the Laemmli sample buffer (62.5 mM
Tris–HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% bromo-
phenol blue) plus 0.5% dithiotreitol (DTT). Sample mix-
tures were boiled at 95C for 5 min, and then denaturated
samples were loaded in duplicate onto 10 well 12% SDS-
PAGE. To ensure optimal band resolution, the electro-
phoretic run was carried out in a minigel slab apparatus
(Bio-Rad), using TGS running buffer (25 mM Tris–HCl,
192 mM glycine, 0.1% SDS, pH 8.3). Electrophoresis was
initially run at 100 V for 30 min, followed by an increase
up to 200 V, until the dye front reached the bottom of the
gel. Finally, urinary proteins were visualized by incubation
for at least 4 h in colloidal Coomassie Blue G-250, under
gentle shaking, and later destained with 5% acetic acid. To
verify the experiment reproducibility, distinct gels were
stained with a more sensitive silver nitrate staining proto-
col, as previously described in detail [21].
Image analysis
Gel images were acquired by a calibrated densitometer
(Bio-Rad GS800) and analyzed by the powerful 1-D image
analysis software program ‘‘Quantity One’’ (Bio-Rad). This
software allows the identiﬁcation of differentially expressed
proteins in the different groups, and accurately detects
increased or decreased proteins on the basis of spots stain-
ing intensity. The imaging device supported by this soft-
ware is a light detector that converts signals from biologic
samples into digital data, and subsequently displays the data
in the form of a gray-scale. The total intensity of protein
band is obtained by the sum of the intensities of all the
pixels that make up the band, and the signal intensity is
expressed as optical density (OD). Lane-based quantitation
involves calculating the average intensity of pixels across
the band’s width and integrating over the band’s height. In
order to compensate for differences in intensity between
lanes and correct the variability due to the staining methods,
the band volumes were normalized as a percentage of the
total OD of all the bands present in the gel. Moreover, to
minimize background and noise density in the image
maintaining data integrity, a lane-based background sub-
traction was performed. The protein bands were quantita-
tively, qualitatively, and statistically analyzed.
Mass spectrometry analysis
The bands of interest were excised from the gels and
analyzed by a quadrupole-time of ﬂight liquid chroma-
tography-mass spectrometry (Q-TOF LC/MS). Brieﬂy,
protein bands were de-stained using acetonitrile, reduced
with DTT and alkylated with iodoacetamide, and subse-
quently digested with trypsin overnight at 37C. After
digestion, the peptides were ﬁrst extracted with acetoni-
trile/ammonium bicarbonate, followed by a second
extraction with formic acid. Finally, the pooled peptides
extracted were concentrated in a vacuum drier and exam-
ined using the 6520 Accurate-Mass Q-TOF LC/MS (Agi-
lent Technologies Inc., CA, USA), as previously fully
described [22].
Statistical analysis
Student’s t-test, with selected level of signiﬁcance set at the
probability value \0.05, and Bonferroni correction were
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123used to compare demographic and clinical data of MOH
patients and control group (Table 1). Odds ratio (OR) and
risk ratio (RR) were used to evaluate non-parametric values
of protein proﬁles (Table 3), because in control subjects
and in triptans and mixtures abusers most bands were not
detectable. In both tables, all data are provided as
mean ± standard deviation (SD).
Results
Demographic and clinical characteristics of MOH patients
and control subjects are reported in Table 1. Data were
compared using the Student’s t-test and the Bonferroni
correction. The unique signiﬁcant difference was related to
age, and was found in the mixtures group vs. control and
triptans groups.
In order to characterize the urinary proteomic proﬁle of
each group, urine proteins were separated by SDS-PAGE
analysis, according to their molecular weight (MW), as
showninFig. 1.Excellentreproducibilityamongthevarious
experiments was indicated by an accurate and total over-
lapping of the deﬁnite protein pattern obtained from dupli-
categels.Moreover,CoomassieBluestaininggavethesame
results as silver nitrate staining protocol (data not shown).
Comparing the patients proteomic proﬁles with those of
healthy controls, we revealed a different protein expression
at various MW levels (OR = ?). The signiﬁcantly dif-
ferent bands were excised from the gels and analyzed by
Q-TOF LC/MS, after trypsin digestion. A representative
mass spectrum concerning the identiﬁcation of UROM is
illustrated in Fig. 2. The protein sample was ionized pro-
ducing charged molecules (ions), which were separated on
the basis of their mass-to-charge ratio (m/z) in an electro-
magnetic ﬁeld, and then the ion signals produced were
processed into mass spectra. All the identiﬁed proteins are
listed in Table 2. In column 1 are reported the protein entry
names derived from the UniProt knowledge database, all
with extension ‘‘Human’’. Entry names corresponded to
those indicated in Fig. 1. Column 2 denotes the UniProt
database primary protein accession number, column 3 the
recommended and commonly used protein name and col-
umn 4 the gene name. Column 5 refers to the probability
based ions scores, associated with the queries. Ions score is
-10 9 Log(P), where P is the probability that the observed
match between the experimental data and the database
sequence is a random event. Individual ions scores [25
indicate identity or extensive homology. Protein scores are
derived from ions scores as a non-probabilistic basis for
ranking protein hits. The query values designate the num-
ber of peptides that match the identiﬁed protein (setting at
least ten matching peptides). Column 6 shows the sequence
coverage, namely the percentage of amino acids sequenced
for each detected protein, and the last column displays their
main function. The listed proteins were selected consider-
ing the highest scores, queries, and the greater amino acids
sequence coverage among all the proposed identiﬁcations.
By subjecting protein bands to densitometry with the
Quantity One software (Bio-Rad), it turned out that the
total OD in lane A (controls) was 24,000, whereas that of
lane B (triptans) was 20,500, for lane C (NSAIDs) was
49,200, and for lane D (mixtures) was 35,500. Noteworthy
is that the total OD of proteins present in NSAIDs lane was
twice as much, in abundance, in comparison with controls.
The mean OD of each differential protein band is reported
in Table 3. The more signiﬁcant differences, as also clearly
evident in Fig. 1, emerged within the group of healthy
controls (lane A) and NSAIDs patients (lane C), since
seven proteins (enclosed in rectangle) resulted over-secre-
ted from kidney: uromodulin (UROM), a-1-microglobulin
(AMBP), zinc-a-2-glycoprotein ZAZG), inter-a-trypsin
heavy chain H4 (ITIH4), Ig kappa chain C region (IGKC),
non-secretory ribonuclease (RNAS2), and cystatin-C
(CYTC) (OR = 49, 95% CI 2.53–948.67; RR = 7, 95% CI
1.09–44.60 vs. controls OR = 11.6, 95% CI 0.92–147.57;
RR = 5, 95% CI 0.74–33.77 vs. triptans and mixtures
groups). In particular, at high MW, all patients groups
showed a very intensive protein band, corresponding to
250-
150-
100-
75-
50-
37-
25-
20-
15-
10-
MW       A            B          C          D
High MW
Medium MW
Low MW
UROM
IGKC
ITIH4
ZAZG
AMBP
CYTC
RNAS2
CYTM
Fig. 1 SDS-PAGE proﬁling of urinary proteins from control subjects
(lane A), triptans (lane B), NSAIDs (lane C), and mixtures (lane D)
abusers. MW molecular weight marker ladder (Precision Plus protein
standard, Bio-Rad). In boxes are enclosed the differential protein
bands among groups, and on the right side of the ﬁgure are reported
the entry names of the proteins identiﬁed by MS analysis; UROM
Uromodulin, ITIH4 Inter-a-trypsin inhibitor heavy chain H4, ZAZG
Zinc-a-2 glycoprotein, AMBP a-1-microglobulin, IGKC Immuno-
globulin kappa chain C region, RNAS2 Non-secretory ribonuclease 2,
CYTC Cystatin-C, CYTM Cystatin-M
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123UROM, which was much less visible in controls. At
medium MW (range 25–70 kDa), ITIH4 plus IGKC, and
RNAS2 resulted up-regulated not only in the NSAIDs
group, but also in mixtures abusers (lane D) and in triptans
patients (lane B), respectively (OR = 4.2, 95% CI
0.33–53.12; RR = 1.4, 95% CI 0.77–2.54 vs. controls).
Finally, at low MW (11–20 kDa), the CYTM was found
up-regulated only in the triptans group.
In addition, four bands around 50 kDa were most evi-
dent in lane A (control group) compared to patient groups,
and were identiﬁed as albumin fragments (data not shown).
Furthermore, the intense band above (75 kDa), present in
all groups, corresponded to serum albumin (ALBU, Acc.
No. P02768). In urine, albumin exists in two forms: native
(a single polypeptide) and a modiﬁed form comprised of
large fragments. Infact, it is well demonstrated that ﬁltered
albumin is excreted as an heterogeneous population of
albumin-derived molecules resulting from extensive deg-
radation ([90%) during renal passage, to produce frag-
ments that are excreted in urine [23].
Fig. 2 An example of a
representative mass spectrum
(obtained after ionization of
UROM protein by Q-TOF LC/
MS), illustrating the distribution
of ions by mass-to-charge ratio
(m/z) and relative abundance
(intensity)
Table 2 Differentially expressed proteins identiﬁed by Q-TOF LC/MS analysis
Entry name Accession n. Protein name Gene name Score/queries Cov. (%) Primary function
UROM P07911 Uromodulin (or Tamm-Horsfall
urinary glycoprotein)
UMOD 8131/525
a 41
a Regulation
2781/192
b 32
b
7532/480
c 39
c
AMBP P02760 Alpha-1-microglobulin AMBP 1218/161
b 56
b Inhibition
ZAZG P25311 Zinc-alpha-2-glycoprotein AZGP1 589/53
b 30
b Lipid degradation
ITIH4 Q14624 Inter-a-trypsin heavy chain H4 ITIH4 500/63
b 42
b Acute phase reaction
390/71
c 50
c
IGKC P01834 Ig kappa chain C region IGKC 2396/141
b 93
b Immune response
2609/142
c 93
c
RNAS2 P10153 Non-secretory ribonuclease RNASE2 571/51
a 21
a Multifunction
468/44
b 21
b
CYTM Q15828 Cystatin-M CST6 80/10
a 28
a Protease inhibitor
CYTC P01034 Cystatin-C CST3 172/13
b 23
b Inhibition/Regulation
Entry name UniProt knowledge database entries, all with extension _HUMAN. Entry names corresponded to those reported in Fig. 2, Accession
n primary accession number from UniProt database, Score: the highest scores obtained using MASCOT search engine, Queries number of
peptides that match the identiﬁed protein (at least ten matching peptides), Cov. (coverage) percentage of amino acids sequenced for each detected
protein
a values detected in triptans group
b values detected in NSAIDs group
c values detected in mixtures group
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At ﬁrst, some data shown in Table 1 need to be discussed
to clarify the studied population. Among the groups there
was a difference in age only in the mixture users versus
triptans and control subjects. This difference could be
explained by two observations: ﬁrstly, patients assuming
analgesic mixtures are historically older, when the clinical
practice for treatment of chronic headache was based on
the use of classic mixtures, as association of caffeine,
phenothiazines or barbiturates and NSAIDs. The second
one is that the use of mixtures comes after the incoming
loss of efﬁcacy of simple NSAIDs, so these are the patients
with longer histories of headaches. All the other clinical
and headache parameters did not differ signiﬁcantly within
groups. Interestingly, there were no differences between
users of mixtures, drugs with a noticeable addiction risk,
and triptans, which have never shown potential addictive
activity in animal tests. Moreover, all blood and urine
analysis were in the normal range, also in individuals with
30 and more years of daily drug intake.
Urine samples are used to study renal physiology and
kidney diseases, as it contains useful biologic protein
markers. Actually, disorders which adversely affect the
function of the kidney can cause impaired proteins reab-
sorption and consequently their excessive losses in the
urine. Direct nephrotoxic consequences may occur both in
glomerular and tubular cells, as a result of different
mechanisms, such as disruption of normal cellular func-
tions, induction of intratubular obstruction, cellular swell-
ing and tubular luminal occlusion [24].
One feasible approach to address renal drug effects is the
employment of multiparametric tests, e.g., the innovative
genomics, metabolomics and proteomics based assays that
enable the simultaneous assessment of several parameters.
During the past few years, proteomics has been extensively
applied to various ﬁelds of medicine, including nephrology
[25]. Particularly, proteomic analysis for nephrotoxicity
was ﬁrst introduced by Aicher et al. [26] to determine the
association between renal protein changes and cyclosporine
A nephrotoxicity in renal transplant patients. Afterwards,
some proteomic studies were conducted on rat urine, e.g., to
ﬁnd out renal effects of puromycin aminonucleoside [27],
or, more recently, of cisPlatin, to discover drug-induced
renal cytotoxicity biomarkers [28].
While adverse effects from long-term triptans use are
unknown, the overuse of analgesics may cause well-known
unwanted events, including liver dysfunction, gastrointes-
tinal bleeding, renal insufﬁciency, and addiction [29].
Several research studies developed over the past 15 years
reported the evidence of NSAIDs-induced kidney dys-
functions, such as acute renal failure and electrolyte
imbalance. Nonetheless, the exact mechanism(s) of neph-
rotoxicity remains still unclear, though most theories focus
on the initial inhibition of the cyclooxygenase (COX), the
enzyme involved in prostaglandins (PG) synthesis, pro-
ducing vasoconstriction and the subsequent perturbation of
the numerous actions of COX in the kidney [30].
Despite all this evidence, at present no studies have yet
been performed in the attempt to search for possible early
biomarkers of kidney damages in MOH patients.
Remarkably, these patients represent a speciﬁc model
because they do not have any chronic systematic diseases,
such as immunologic and cardiovascular disorders or
hypertension; hence, this population is a model of healthy
subjects who assume daily doses of analgesic drugs from
many years. In this perspective, we can consider the use of
NSAIDs and triptans as the unique possible cause of kidney
impairment, and its early modiﬁcations can be investigated
by proteomics.
In the present study we deﬁned a preliminary and basic
urinary proteomic proﬁle of MOH. The most evident and
Table 3 Optical densities of differentially expressed proteins in control subjects and MOH patients
Control group Triptans group NSAIDs group Mixtures group
UROM 2,205 ± 291 14,800 ± 2,764 12,500 ± 1,652 11,100 ± 982
AMBP ND ND 9,650 ± 1,393 ND
ZAZG ND ND 6,580 ± 969 ND
ITIH4 ND ND 5,760 ± 941 7,560 ± 746
IGKC ND ND 6,200 ± 876 5,480 ± 1,216
RNAS2 ND 1,230 ± 231 1,450 ± 181 ND
CYTM ND 1,125 ± 192 ND ND
CYTC ND ND 1,340 ± 198 ND
Optical densities, detected by ‘‘Quantity One’’ 1-D image analysis software (Bio-Rad), were expressed as means ± standard deviation. Seven
proteins were over-secreted in NSAIDs group: OR = 49, 95% CI 2.53–948.67; RR = 7, 95% CI 1.09–44.60 vs. controls; OR = 11.6, 95% CI
0.92–147.57; RR = 5, 95% CI 0.74–33.77 vs. triptans and mixtures groups. Three proteins were over-secreted in triptans and mixtures groups:
OR = 4.2, 95% CI 0.33–53.12; RR = 1.4, 95% CI 0.77–2.54 vs. controls
ND protein not-detectable in the sample
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123unquestionable result is the ﬁnding of a marked presence of
UROM in all patients groups, compared with control sub-
jects (Fig. 1). UROM (also known as Tamm–Horsfall
protein) is a large glycoprotein exclusively synthesized in
the kidney and secreted into the urine via proteolytic
cleavage. Its physiologic role is still not fully established.
Nevertheless, it seems very likely that this protein is
involved in the development of cast nephropathy, forma-
tion of renal stones, immunologic defence in the kidney, as
well as in the modulation of systemic immunologic events
[31]. Urinary UROM has also been postulated as a suitable
parameter for determining the functional state of the kid-
ney. Very recently, polymorphisms in the UROM gene
have been found responsible for increased urinary UROM
production and for an elevated risk to develop chronic renal
alterations, such as the so-called familial juvenile hyperu-
ricemic nephropathy, medullary cystic kidney disease and
glomerulocystic kidney disease [32]. Other identiﬁed pro-
teins which resulted over-secreted from kidney in MOH-
NSAIDs abusers include AMBP, ZAZG and CYTC.
AMBP is a stable urinary indicator protein, which reﬂects
acute and chronic dysfunctions of the proximal renal
tubule. This protein has an immunomodulatory role, with a
broad spectrum of possible clinical applications, besides
being a promising marker for evaluation of tubular function
[33]. High concentrations in urine were found to be
indicative of tubular drug toxicity, interstitial nephritis or
chronic renal failure. Furthermore, determination of uri-
nary AMBP has been used to screen for nephropathy due to
environmental hazards, like intoxications with heavy met-
als [34]. Regarding ZAZG, Kumar et al. [35] detected this
protein, by proteomic analysis, in urine of patients with
different renal diseases, such as nephrotic syndrome, kid-
ney failure and microalbuminuria. They supposed that
ZAZG, together with other tubular damage markers iden-
tiﬁed in their study (including AMBP), could probably to
be suggestive of ﬁrst stages of renal tubular injury. Lastly,
CYTC has been widely proposed as an accurate biomarker
of glomerular ﬁltration for the early detection of acute
kidney injury (AKI) [36]. CYTC is a low-MW protein that,
due to its relatively small size, normally is freely ﬁltered at
the glomerulus and then proteolytically digested and/or
completely reabsorbed along the nephron. Tubular damage
in AKI impairs this latter process and allows for this pro-
tein to appear in the urine, thus making it potentially
suitable as a marker of AKI [37]. Recently, it was reported
that immunohistochemical CYTC expression in the proxi-
mal tubule was altered by some glomerular and/or tubular
nephrotoxicants in rats [38]. Moreover, we discovered
other two proteins, namely ITIH4 and IGKC, clearly
associated with NSAIDs and mixtures overuse. ITIH4 is
involved in the pathogenesis of calcium oxalate lithiasis
and has been recently linked to urinary stones disease [39],
while immunoglobulin free light chains may cause kidney
injury affecting all its compartments, in a broad variety of
disease patterns [40]. Finally, regarding RNAS2 (found in
both NSAIDs and triptans abusers), and CYTM (revealed
only in triptans), so far no correlation have been reported
between these proteins and renal disorders.
These ﬁndings suggest that the consumption of a mix-
ture of drugs seems to be safer than the use of NSAIDs
with regards to the possibility to induce nephrotoxicity in
MOH patients. This is even more evident for triptans, since
in this group we detected only one protein potentially
related with renal toxicity. Actually, based on the available
literature, all the 6 proteins that we found signiﬁcantly
higher in urine of NSAIDs abusers (excluding RNAS2)
have demonstrated a reasonable correlation with different
types of kidney dysfunctions. However, it is important to
outline that all the study participants did not show any sign
of renal damage, and in our clinical practice we did not
register patients who developed renal impairment, except
in a case with concomitant arterial hypertension.
In conclusion, proteomic technology proved to be a
promising tool for the characterization of the urinary prote-
omeinnephrotoxicologicresearch,anditsapplicationinthis
ﬁeld may provide prognostic, therapeutic and monitoring
guidance for MOH patients. This study offers the basis for
subsequent perspective works directed toward better deﬁn-
ing this problem and to conﬁrm and extend the present
results, using further specialized proteomic strategies.
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